

Dr. Tali Kizhner



Could you introduce yourself and tell us about your company's unique mission in the exosome space?

My name is Dr. Tali Kizhner, and I have 15+ years of experience directing R&D and CMC at leading companies, including Protalix Biotherapeutics, Biond Biologics Ltd, and International Fragrance and Flavors, with contributions to novel biopharma advancements, including FDA- and EMEA-approved biologics, intracellular delivery, and dietary supplements.

Nurexone's mission is to apply the superpower of exosomes in the field of regenerative medicine, focusing on central nervous system injuries. Exosome-based therapies hold immense potential to provide targeted and highly effective solutions for conditions that currently have limited treatment options. Our first drug candidate, ExoPTEN, is designed to break through the barriers that have long prevented true neural repair and functional recovery. We have seen great preclinical results and look forward to the first in human, expected in 2026.

From your perspective, what is the single biggest hurdle (be it in manufacturing, clinical translation, or regulation) that the EV field must overcome to realize its full potential?

Success in preclinical development and studies is the first stepping stone on the challenging path to an approved drug.



Based on personal experience with new drug programs, I believe that the biggest challenge is reaching the point of proven clinical benefit.

Looking ahead, what innovation or breakthrough on the horizon are you most excited about, and how do you see it transforming the development of EV therapies in the next 3-5 years?

I assume AI will have a tremendous impact in our arena and expect to see it shortening development timelines. Moreover, advanced characterization and quantification technologies will allow significantly improved manufacturing and quality control in the exosome area.



**Exosomes
Europe**
by informa...

November 4-5 2025
Amsterdam Marriott Hotel,
Amsterdam, Netherlands

Without giving too much away, what is the key takeaway you hope the audience will get from your specific presentation at Exosomes Europe?

I hope people will realize that we are trying something very new and very bold with strong preclinical results. NurExone, as far as I know, is the only company using exosomes as targeted delivery system for siRNA in spinal cord injury in this way. It is early, but we believe it can be a real breakthrough.

My wish is that the audience will relate to and share our excitement and energy for this direction with its potential to improve millions of lives.

What are you most looking forward to at the meeting in Amsterdam?

Interesting discussions, great networking, new faces and dreams of great applicative science.



NurExone will be joining us at Exosomes Europe this November in Amsterdam. Register Now.

